We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Perlegen and 454 to Collaborate in Drug Response Sequencing Study
News

Perlegen and 454 to Collaborate in Drug Response Sequencing Study

Perlegen and 454 to Collaborate in Drug Response Sequencing Study
News

Perlegen and 454 to Collaborate in Drug Response Sequencing Study

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Perlegen and 454 to Collaborate in Drug Response Sequencing Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Perlegen Sciences, Inc., and 454 Life Sciences, part of Roche Diagnostics, announced a collaboration to conduct large scale genetic re-sequencing in hundreds of human DNA samples collected by Perlegen from individuals with specific responses to a widely prescribed class of drug.

The goal of the collaboration will be to determine whether sufficient genetic variation can be identified and validated to create a clinical test that will predict how individuals might respond to this class of medicines.

Pursuant to the terms of the agreement, Perlegen and 454 will each re-sequence select portions of the genome within each sample, using 454 Sequencing™ technology and DNA amplified with Perlegen’s proprietary sample preparation and amplification technologies. The parties’ data analysis teams will jointly study the combined results to determine how significant a role variations in genetic sequence plays in patient response to this drug class.

“We are pleased to be working with 454 in this landmark pharmacogenomic study that combines 454’s exceptional next generation sequencing technology with Perlegen’s expertise in defining genetic variation on a carefully selected sample set,” commented Bryan Walser, MD, Chief Executive Officer of Perlegen Sciences. “This study holds the promise to improve therapeutic outcomes for a vast number of patients.”

Advertisement